Paradigm Biocapital Advisors LP
"13F equity value" = market value of this filer's US-listed long equity positions only. It excludes cash, bonds, non-US and short positions, so it understates a fund's true assets under management — often by a lot.
13F holdings are disclosed ~45 days after quarter-end, and they never reveal when within the quarter a fund actually bought. So any 13F-based summary is structurally late and blurred — this applies to every fund, including this one.
We backtested copying it anyway. Buying this fund's new positions the day each filing went public, over 16 quarters, returned +4.4% per quarter — versus +3.3% per quarter from simply owning every 13F stock. It beat that baseline in only 50.0% of quarters (excess t = 0.48, not statistically significant). Its filings tell you what it bought — not what you should buy.
Quarterly compounding, invested quarters only · entry 47 days after quarter-end (when 13F data becomes public)
Top 20 holdings of 35 · 2026 Q1
| Ticker | Value | Weight | QoQ |
|---|---|---|---|
| ACLX | $663M | | HOLD |
| RVMD | $647M | | HOLD |
| NUVL | $545M | | HOLD |
| PCVX | $279M | | ADD |
| EWTX | $232M | | ADD |
| GMAB | $214M | | ADD |
| INSM | $205M | | NEW |
| TARS | $180M | | HOLD |
| BLTE | $178M | | NEW |
| ERAS | $168M | | TRIM |
| CNTA | $142M | | NEW |
| OLMA | $120M | | ADD |
| TERN | $117M | | ADD |
| ORKA | $114M | | ADD |
| APGE | $113M | | ADD |
| SYRE | $99M | | ADD |
| CYTK | $98M | | NEW |
| ABVX | $86M | | TRIM |
| TNGX | $84M | | NEW |
| MAZE | $82M | | NEW |
QoQ vs previous quarter's share count · NEW = new position · ADD/TRIM = ±2% shares · HOLD = unchanged.
New positions in 2026 Q1
Method & Limitations
Method: a "new position" = held this quarter, absent last quarter (options excluded; stocks with <50 prior holders excluded to filter spin-off artifacts). Entry 47 days after quarter-end — the first day the public could act on the filing. Benchmark = equal-weighted universe of all 13F-held stocks. Limitations: quarterly snapshots can't see intra-quarter trades; survivorship bias — funds that shut down are absent, which flatters the sample. Statistics, not advice.